Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible health research updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: Tear-based testing picked up a Parkinson’s-related protein signal, mindfulness training helped people with gaming addiction and depression, early lab work flagged RORγ as a kidney-protection target, a new RYK–GPNMB pathway showed how MASH may start and how it might be blocked, and exosome-carried sulforaphane improved fertility measures in rats; no FDA press announcements were posted today.

Good news: A short mindfulness program helped people with both video game addiction and depression. They felt less depressed and had fewer cravings than the comparison relaxation program.

The effect and neural changes underlying mindfulness meditation training in patients with comorbid internet gaming disorder and depression: A randomized clinical trial

Market readiness: 🙂🙂🙂🙂🙂 (This is a non-drug program that can be offered now in the US by trained providers; no new FDA product approval is needed.)

Good news: Researchers found a way to test tear drops for a Parkinson’s disease signal. The test found the signal in many people with Parkinson’s and stayed negative in people without related diseases.

Detection of alpha-synuclein seeding activity in tear fluid in patients with Parkinson’s disease

Market readiness: 🙂🙂 (Early human proof-of-concept; it needs larger studies and a standardized clinical lab test before routine use.)

Good news: Scientists found a body “switch” (RORγ) that helps protect kidneys in diabetes and aging models. Turning this switch up helped reduce kidney injury, which could lead to new treatments later.

Energy-sensing molecule RORγ regulates cholesterol metabolism and immune signaling in diabetic kidney disease and aging

Market readiness: 🙂 (This is still lab and animal-mechanism research; it is not yet a tested treatment for people.)

Good news: Researchers found a new trigger pathway for fatty liver disease (MASH) and showed multiple ways to block it that helped prevent and treat MASH in preclinical models. This opens new paths for future medicines.

RYK is a GPNMB receptor that drives MASH

Market readiness: 🙂 (Preclinical work; these strategies would need human safety testing and clinical trials first.)

Good news: In rats with chemo-like fertility damage, delivering sulforaphane inside exosomes helped sperm production recover. Sperm count and movement improved, and testis tissue looked healthier.

Targeted activation of Nrf2 via sulforaphane-loaded exosomes attenuated azoospermic condition in the rat model

Market readiness: 🙂 (Animal-study stage; it’s far from a consumer-ready fertility treatment in the US.)

Thank you for taking the time to take care of yourself and your loved ones.